Argenx

ARGXApproved

argenx is a Dutch-American biotechnology company focused on developing innovative antibody therapies for patients suffering from severe autoimmune diseases and cancer. Founded in 2008, the company has successfully commercialized VYVGART® (efgartigimod) for myasthenia gravis and is advancing multiple programs leveraging its proprietary SIMPLE Antibody™ platform. With operations in the Netherlands, Belgium, and the United States, argenx has established itself as a leader in FcRn antagonist therapies and immunology drug development.

Market Cap

$41.1B

Employees

1,000-1,500

Focus

Biotech

ARGX · Stock Price

USD 663.93+362.93 (+120.57%)

Historical price data

AI Company Overview

Technology Platform

SIMPLE Antibody™ platform focused on FcRn antagonists and complement inhibition for treating autoimmune diseases through selective reduction of pathogenic antibodies.

Pipeline Snapshot

78 drugs in pipeline, 27 in Phase 3

Drug	Indication	Stage
Efgartigimod PH20 SC	Chronic Inflammatory Demyelinating Polyneuropathy	Approved
IV efgartigimod	Myasthenia Gravis Crisis	Approved
Efgartigimod PH20 SC	New Onset Generalized Myasthenia Gravis (gMG)	Approved
Efgartigimod	Myasthenia Gravis Crisis	Approved
Efgartigimod IV	Generalized Myasthenia Gravis	Phase 3

Funding History

Total raised: $234M

IPO$100MUndisclosedMay 18, 2017

Series C$75MForbionMar 15, 2017

Series B$39MLSPJun 15, 2015

Series A$20MForbionJan 15, 2013

FDA Approved Drugs

VYVGART HYTRULOBLAJun 20, 2023

VYVGARTBLADec 17, 2021

Opportunities

Significant expansion potential through VYVGART label extensions across multiple autoimmune indications, with Phase 3 trials in CIDP, ITP, and pemphigus representing multi-billion dollar market opportunities.

Early-stage pipeline programs offer additional long-term growth drivers in complement-mediated diseases and oncology.

Risk Factors

Key risks include intense competition from larger pharmaceutical companies, regulatory execution across multiple Phase 3 trials, manufacturing scale-up challenges, and market access hurdles for premium-priced specialty therapies.

Clinical trial failures could significantly impact valuation and growth trajectory.

Competitive Landscape

argenx competes with established immunology leaders like Roche, AbbVie, and J&J, while differentiating through its specialized FcRn expertise and proven commercial execution. The company faces emerging competition from other FcRn antagonist developers but maintains a first-mover advantage in this therapeutic class.

Publications

Pipeline

FDA Approvals